• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BLCO

    Bausch + Lomb Corporation

    Subscribe to $BLCO
    $BLCO
    Ophthalmic Goods
    Health Care

    Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.

    IPO Year: 2022

    Exchange: NYSE

    Website: https://www.bausch.com

    Recent Analyst Ratings for Bausch + Lomb Corporation

    DatePrice TargetRatingAnalyst
    5/2/2025$20.00 → $15.00Buy
    H.C. Wainwright
    3/28/2025$24.00 → $15.00Overweight → Equal Weight
    Wells Fargo
    12/11/2024$24.00 → $22.00Buy → Neutral
    Citigroup
    12/2/2024$19.00Overweight → Equal-Weight
    Morgan Stanley
    10/15/2024$19.00 → $25.00In-line → Outperform
    Evercore ISI
    7/10/2024$19.00Outperform
    Raymond James
    5/6/2024$16.00 → $18.00Equal-Weight → Overweight
    Morgan Stanley
    1/4/2024$19.00 → $17.00Outperform → In-line
    Evercore ISI
    12/12/2023$16.00Hold
    Stifel
    10/3/2023$20.00Outperform
    Evercore ISI
    See more ratings

    Bausch + Lomb Corporation Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • CEO and Chairman of the Board Saunders Brent L bought $505,067 worth of shares (32,250 units at $15.66) and was granted 32,250 shares, increasing direct ownership by 11% to 627,419 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      8/7/24 5:29:48 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    Bausch + Lomb Corporation Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bausch + Lomb Receives European CE Mark Approval for Preloaded LuxLife® Full Range of Vision Intraocular Lens

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced CE Mark approval for the LuxLife full range of vision intraocular lens (IOL). The preloaded IOL provides patients with natural, continuous vision, from distance to near. Today's announcement reinforces Bausch + Lomb's commitment to equip cataract surgeons with choices to fit the right lens to the right patient following the recent launches of enVista® Envy™ full range of vision lenses in the United States and Canada and enVista Aspire™ intermediate-optimized IOLs in Europe. "This platform has delivered both quality of vision and patient satis

      5/7/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces First-Quarter 2025 Results

      Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

      4/30/25 6:57:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Returning enVista® Intraocular Lenses to Market Following Voluntary Recall

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced it has identified the event that led to its recent voluntary recall of intraocular lenses (IOLs) on the enVista platform. Now that the cause and affected lots have been confirmed, the company will return these models to market. "We voluntarily recalled these lenses because patient safety dictates every decision we make," said Brent Saunders, chairman and CEO, Bausch + Lomb. "We wouldn't bring them back without full confidence in the enVista safety profile, which has been established over years and hundreds of thousands of implants." Investig

      4/24/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Reports More Than 100 Million Units of Contacts Lenses, Lens Care and Eye Care Materials Collected Through ONE By ONE and Biotrue® Eye Care Recycling Programs

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its exclusive ONE by ONE Recycling and Biotrue Eye Care Recycling programs have collected a total of 103,169,500 units, or 625,026 pounds, of used contact lenses, eye care and lens care materials in the United States. That's equivalent to the weight of approximately 600 concert grand pianos1. "These award-winning recycling programs continue to drive a positive environmental impact, offering eye care professionals, patients and consumers a way to properly recycle used eye health materials," said Amy Butler, Vice President, Global Environment,

      4/21/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Voluntary Recall of enVista Aspire™, enVista Envy™ and Certain enVista® Monofocal Intraocular Lenses

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced a voluntary recall of intraocular lenses (IOLs) on its enVista platform. This action was taken out of an abundance of caution after the company received reports of complications, the cause of which could not immediately be explained. "As much as we believe in the enVista platform, patient safety will always be our number one priority," said Brent Saunders, chairman and CEO, Bausch + Lomb. "Surgeons and patients trust Bausch + Lomb, and I believe that this voluntary recall is the best thing we can do to honor that trust." The recall is in res

      3/27/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date:     Wednesday, April 30, 2025   Time:     8 a.m. ET   Webcast:     https://www.webcaster4.com/Webcast/Page/2883/51713   Participant Event Dial-in:     +

      3/26/25 7:45:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of Arise, a lens fitting system that uses intelligent, cloud-based technology to streamline the orthokeratology lens design process. Arise seamlessly syncs directly with topographers – diagnostic tools that capture 3-D images of the eye – to create precise lens designs in seconds to treat myopia. These lenses include the first orthokeratology lens design with toric peripheral curves* approved by the U.S. Food and Drug Administration to treat myopia overnight. Myopia, or nearsightedness, is one of the most common ocular disorde

      3/17/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

      Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results Revenue of $4.791 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $317 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $878 Million Revenue Grew 16% as Reported and 17% on a Constant Currency1 Basis Compared to the Full Year of 2023, with Growth Across All Segments Baus

      2/19/25 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Provides Update on Potential Sale

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following update on a potential sale, which was disclosed in December 2024 following a regulatory request: "Taking Bausch + Lomb private with a third-party buyer was one of several options being explored to complete a full separation from Bausch Health Companies Inc. After engagement with potential buyers, that process is complete, and will not result in a transaction at this time. "Full separation remains the goal. Bausch + Lomb continues to operate as its own entity and execute on its strategies and business plan. The company, which raised 20

      2/6/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, February 19, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/51712 Partici

      1/22/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    Bausch + Lomb Corporation Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Von Eschenbach Andrew C. bought $19,925 worth of shares (1,695 units at $11.76), increasing direct ownership by 4% to 41,748 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/6/25 4:30:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Robertson Russel C was granted 2,210 shares, increasing direct ownership by 5% to 44,576 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/5/25 4:02:01 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Director Paulson John was granted 1,887 shares, increasing direct ownership by 4% to 49,627 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      5/5/25 4:00:47 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Officer Stewart Andrew J. covered exercise/tax liability with 3,954 shares, decreasing direct ownership by 6% to 62,930 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      4/25/25 4:06:52 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • EVP & Chief Legal Officer Bailey A Robert D covered exercise/tax liability with 9,781 shares, decreasing direct ownership by 5% to 170,576 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      4/25/25 4:05:50 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • President,Surgical Bonnefoy Luc covered exercise/tax liability with 4,139 shares, decreasing direct ownership by 5% to 74,351 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      3/3/25 4:22:54 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SVP, Controller and CAO Munsch Frederick was granted 18,581 shares, increasing direct ownership by 35% to 71,294 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      2/28/25 4:31:42 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • President,Surgical Bonnefoy Luc was granted 23,423 shares, increasing direct ownership by 43% to 78,490 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      2/28/25 4:30:40 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Officer Stewart Andrew J. was granted 23,423 shares, increasing direct ownership by 54% to 66,884 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      2/28/25 4:29:38 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • EVP of R&D and CMO Hashad Yehia was granted 25,225 shares, increasing direct ownership by 27% to 119,580 units (SEC Form 4)

      4 - Bausch & Lomb Corp (0001860742) (Issuer)

      2/28/25 4:28:35 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    Bausch + Lomb Corporation Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Bausch + Lomb Corporation

      SC 13G - Bausch & Lomb Corp (0001860742) (Subject)

      2/14/23 5:14:30 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    Bausch + Lomb Corporation Financials

    Live finance-specific insights

    See more
    • Bausch + Lomb Announces First-Quarter 2025 Results

      Revenue of $1.137 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $212 Million Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $126 Million Revenue Grew 3% as Reported and 5% on a Constant Currency1 Basis Compared to the First Quarter of 2024 Updating Full-Year 2025 Guidance to Reflect Estimated One-Time Impact of enVista® Intraocular Lenses Voluntary Recall and Impact of Foreign Exchange Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2025 financial results. "Our core business is performing well, and we remain focused on positioning

      4/30/25 6:57:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release First-Quarter 2025 Financial Results on April 30

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 30, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date:     Wednesday, April 30, 2025   Time:     8 a.m. ET   Webcast:     https://www.webcaster4.com/Webcast/Page/2883/51713   Participant Event Dial-in:     +

      3/26/25 7:45:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Fourth-Quarter and Full-Year 2024 Results, Provides 2025 Guidance

      Fourth-Quarter 2024 Financial Results Revenue of $1.280 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $3 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $259 Million Revenue Grew 9% as Reported and 11% on a Constant Currency1 Basis Compared to the Fourth Quarter of 2023, with Growth Across All Segments Full-Year 2024 Financial Results Revenue of $4.791 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $317 Million Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $878 Million Revenue Grew 16% as Reported and 17% on a Constant Currency1 Basis Compared to the Full Year of 2023, with Growth Across All Segments Baus

      2/19/25 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2024 Financial Results on February 19

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarter and full-year 2024 financial results on Wednesday, February 19, 2025. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, February 19, 2025 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/51712 Partici

      1/22/25 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Acquires Elios Vision, Significantly Enhances Glaucoma Treatment Capabilities

      Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that an affiliate has acquired Elios Vision, Inc., developer of the ELIOS™ procedure, the first clinically validated, minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. The acquisition unlocks new opportunities to treat glaucoma effectively in conjunction with cataract surgery without implants and bolsters Bausch + Lomb's glaucoma portfolio, which features pharmaceutical and surgical approaches. "Today's announcement further demonstrates our commitment to investing in smart, innovative technologies that enable eye c

      12/11/24 6:59:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Third-Quarter 2024 Results

      Revenue of $1.196 Billion GAAP Net Income Attributable to Bausch + Lomb Corporation of $4 Million Adjusted EBITDA (non-GAAP)1 of $212 Million; Adjusted EBITDA excluding Acquired IPR&D (non-GAAP)1 of $227 Million Revenue Grew 19% as Reported and 19% on a Constant Currency1 Basis Compared to the Third Quarter of 2023, Driven by Solid Execution and Growth Across All Segments Raising Full-Year 2024 Revenue Guidance Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its third-quarter 2024 financial results. "Our focus on execution continues to drive growth, with significant opportunity

      10/30/24 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release Third-Quarter 2024 Financial Results on October 30

      Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter 2024 financial results on Wednesday, October 30, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details Date: Wednesday, October 30, 2024 Time: 8 a.m. ET Webcast: https://www.webcaster4.com/Webcast/Page/2883/49633 Participant Event Dial-in: +1 (888) 506-0062 (North A

      10/9/24 8:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces Second-Quarter 2024 Results

      Revenue of $1.216 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $151 Million Adjusted EBITDA (non-GAAP)1 of $209 Million Revenue Grew 17% as Reported and 20% on a Constant Currency1 Basis Compared to the Second Quarter of 2023, Driven by Broad-Based Growth Across All Business Segments Raising Full-Year 2024 Revenue and Adjusted EBITDA (non-GAAP)1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its second-quarter 2024 financial results. "Our continued growth is being fueled by a relentless focus on selling and operational excellence, and a commitmen

      7/31/24 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Will Release Second-Quarter 2024 Financial Results on July 31

      Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter 2024 financial results on Wednesday, July 31, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of the call. Conference Call Details   Date:   Wednesday, July 31, 2024       Time:   8 a.m. ET       Webcast:   https://www.webcaster4.com/Webcast/Page/2883/49632       Participant

      7/11/24 12:05:00 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Announces First-Quarter 2024 Results

      Revenue of $1.099 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $167 Million Adjusted EBITDA (non-GAAP)1 of $180 Million Revenue Grew 18% as Reported and 20% on a Constant Currency1 Basis Compared to the First Quarter of 2023, Driven by Growth Across All Business Segments Foreign Exchange Negatively Impacted Revenue by Approximately $20 Million Raising Full-Year 2024 Constant Currency Revenue Growth1 Guidance Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. "Outperformance from each of our business units and solid

      5/1/24 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    Bausch + Lomb Corporation Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright reiterated coverage on Bausch + Lomb with a new price target

      H.C. Wainwright reiterated coverage of Bausch + Lomb with a rating of Buy and set a new price target of $15.00 from $20.00 previously

      5/2/25 7:51:06 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Bausch + Lomb from Overweight to Equal Weight and set a new price target of $15.00 from $24.00 previously

      3/28/25 8:14:16 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Citigroup with a new price target

      Citigroup downgraded Bausch + Lomb from Buy to Neutral and set a new price target of $22.00 from $24.00 previously

      12/11/24 7:25:38 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Bausch + Lomb from Overweight to Equal-Weight and set a new price target of $19.00

      12/2/24 6:54:01 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Bausch + Lomb from In-line to Outperform and set a new price target of $25.00 from $19.00 previously

      10/15/24 7:27:04 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Raymond James initiated coverage on Bausch + Lomb with a new price target

      Raymond James initiated coverage of Bausch + Lomb with a rating of Outperform and set a new price target of $19.00

      7/10/24 7:25:17 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb upgraded by Morgan Stanley with a new price target

      Morgan Stanley upgraded Bausch + Lomb from Equal-Weight to Overweight and set a new price target of $18.00 from $16.00 previously

      5/6/24 7:28:52 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Bausch + Lomb from Outperform to In-line and set a new price target of $17.00 from $19.00 previously

      1/4/24 8:02:47 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Stifel initiated coverage on Bausch + Lomb with a new price target

      Stifel initiated coverage of Bausch + Lomb with a rating of Hold and set a new price target of $16.00

      12/12/23 6:50:26 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Evercore ISI resumed coverage on Bausch + Lomb with a new price target

      Evercore ISI resumed coverage of Bausch + Lomb with a rating of Outperform and set a new price target of $20.00

      10/3/23 9:34:56 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    Bausch + Lomb Corporation SEC Filings

    See more
    • SEC Form 10-Q filed by Bausch + Lomb Corporation

      10-Q - Bausch & Lomb Corp (0001860742) (Filer)

      4/30/25 4:17:10 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      4/30/25 7:02:13 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form DEF 14A filed by Bausch + Lomb Corporation

      DEF 14A - Bausch & Lomb Corp (0001860742) (Filer)

      4/10/25 4:02:24 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-K filed by Bausch + Lomb Corporation

      10-K - Bausch & Lomb Corp (0001860742) (Filer)

      2/19/25 4:47:47 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      2/19/25 7:01:56 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      11/1/24 4:27:06 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by Bausch + Lomb Corporation

      10-Q - Bausch & Lomb Corp (0001860742) (Filer)

      10/30/24 4:32:15 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Bausch + Lomb Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bausch & Lomb Corp (0001860742) (Filer)

      10/30/24 7:04:33 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form S-8 filed by Bausch + Lomb Corporation

      S-8 - Bausch & Lomb Corp (0001860742) (Filer)

      8/1/24 4:48:38 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by Bausch + Lomb Corporation

      10-Q - Bausch & Lomb Corp (0001860742) (Filer)

      8/1/24 4:17:06 PM ET
      $BLCO
      Ophthalmic Goods
      Health Care

    Bausch + Lomb Corporation Leadership Updates

    Live Leadership Updates

    See more
    • Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors

      Richard De Schutter to Retire from Board Following 2024 Annual Meeting Bausch + Lomb Corporation (TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Karen L. Ling has been appointed to its Board of Directors (the "Board"), effective immediately. Current director Richard De Schutter will retire from the Board effective as of the company's 2024 Annual Meeting of Shareholders (the "Annual Meeting"). With Ms. Ling's appointment, the Board has been temporarily expanded to 11 members and is expected to revert to 10 directors following the Annual Meeting. "Since my return to the company, Richard has been a trusted advisor,

      2/28/24 8:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO

      Papa will lead Emergent into a new era of focusing on protecting public health, returning to growth and paying down the company's debt GAITHERSBURG, Md., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced that its Board of Directors has appointed Joseph C. Papa as president and CEO, effective February 21, 2024. Mr. Papa succeeds Haywood Miller, who will step down from his role as interim CEO, effective February 21, 2024. "Following a thorough search process, we are pleased to appoint Joe Papa as president and CEO of Emergent," sai

      2/21/24 7:00:00 AM ET
      $BLCO
      $EBS
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Bausch + Lomb Appoints Bob Bailey as Executive Vice President and Chief Legal Officer and Andrew Stewart as President, Ophthalmic Pharmaceuticals

      Mr. Bailey and Mr. Stewart Will Join Bausch + Lomb on April 24, 2023 Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointments of Bob Bailey as executive vice president (EVP) and Chief Legal Officer and Andrew Stewart as president, Ophthalmic Pharmaceuticals, effective April 24, 2023. Both Mr. Bailey and Mr. Stewart will join the executive management team of the Company. Concurrent with these appointments, Christina Ackermann will step down from her role as EVP, General Counsel and president, Ophthalmic Pharmaceuticals, and will leave Bausch + Lomb on April

      4/12/23 7:00:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care
    • SparingVision appoints Joseph C. Papa as Chairman

      SparingVision appoints Joseph C. Papa as Chairman Former Bausch and Lomb Chairman and CEO joins as non-executive independent Chairman as SparingVision enters the clinic with first gene agnostic lead program SPVN06 Paris, April 5, 2023 – SparingVision, a clinical-stage genomic medicine company developing vision-saving treatments for ocular diseases, today announces the appointment of Joseph C. Papa as its independent Chairman. Papa brings over 30 years of experience in the healthcare sector, having most recently served as Chief Executive Officer and Chairman at Bausch and Lomb Corporation ("Bausch and Lomb") (NYSE:BLCO) a global eye health company. During his tenure, Papa successfully led

      4/5/23 7:00:00 AM ET
      $BLCO
      $NTLA
      Ophthalmic Goods
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
    • Bausch + Lomb Appoints Brent Saunders as Chief Executive Officer and Chair of the Board of Directors, Effective March 6, 2023

      Mr. Saunders Brings More Than 25 Years of Health Care Leadership to Bausch + Lomb Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, announced the appointment of Brent Saunders as chief executive officer ("CEO") and chair of the Board of Directors ("Board") of the Company, effective March 6, 2023. Concurrent with this appointment, and as previously announced, Joseph C. Papa will step down from his roles as CEO and director. Additionally, effective upon Mr. Saunders' appointment as chair of the Board, Thomas W. Ross, Sr. will become the Lead Independent Director of the Board. To

      2/15/23 6:58:00 AM ET
      $BLCO
      Ophthalmic Goods
      Health Care